US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TransAtlantic Capital Inc.

0.0003

0.0000

Volume:- -

Turnover:- -

Market Cap:43.50K

PE:-0.44

High:0.0003

Open:0.0003

Low:0.0003

Close:0.0003

52wk High:0.0401

52wk Low:0.0000

Shares:145.00M

Float Shares:125.00M

Volume Ratio:0.01

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0007

EPS(LYR):-0.0020

ROE:6.70%

ROA:-45655.00%

PB:-0.21

PE(LYR):-0.15

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TACI"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TACI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TACI\",,,,,undefined,":{"symbol":"TACI","market":"US","secType":"STK","nameCN":"TransAtlantic Capital Inc.","latestPrice":0.0003,"timestamp":1770411600000,"preClose":0.0003,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":125000000,"shares":145000000,"eps":-0.000677,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST Delay","open":0.0003,"high":0.0003,"low":0.0003,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.000677,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0003,"volumeRatio":0.010429701838395566},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TACI\",,,,,undefined,":{"symbol":"TACI","floatShares":125000000,"roa":"-45655.00%","roe":"6.70%","lyrEps":-0.002042,"volumeRatio":0.010429701838395566,"shares":145000000,"dividePrice":0,"high":0.0003,"amplitude":0,"preClose":0.0003,"low":0.0003,"week52Low":0.000001,"pbRate":"-0.21","week52High":0.0401,"institutionHeld":0,"latestPrice":0.0003,"eps":-0.000677,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.000677,"open":0.0003,"prevYearClose":0.0003,"prevWeekClose":0.0003,"prevMonthClose":0.0003,"prevQuarterClose":0.0003,"fiveDayClose":0.0003,"twentyDayClose":0.0003,"sixtyDayClose":0.0003},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TACI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TACI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TACI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TACI\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606871662","title":"Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606871662","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606871662?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:30","pubTimestamp":1769603400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Jan. 28, 2026  -- Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial.\"We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"With his track record of building comprehensive commercial organizations and successfully launching multiple therapeutics, Matt's leadership will be critical in our ambition to change what's possible for patients in need.\". \"I am excited to spearhead our launch readiness activities and guide our evolution into a commercial-stage company,\" said Matt Skel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU0868494617.USD","LU2279689827.SGD","VERA","LU0256863811.USD","IE00BJTD4V19.USD","LU0795875169.SGD","LU0726765562.USD","LU1430594728.SGD","BK4534","LU0795875086.SGD","BK4550","TACI","MCD","BK4566","LU1718418525.SGD","LU2347655156.SGD","BK4139","IE00BJJMRX11.SGD","LU0942090050.USD","LU1074936037.SGD","LU1035773651.USD","BK4209","BK4610","IE00B7KXQ091.USD","LU2133065610.SGD","IE00BJTD4N35.SGD","LU1585245621.USD","LU1069347547.HKD","BK4585","IE00BFSS8Q28.SGD","BK4539","IE0004445015.USD","BK4504","LU0868494708.USD","FSGS","IE00BJJMRY28.SGD","IE00BFSS7M15.SGD","LU1732799900.SGD","BK4588","BK4581","LU1244550221.USD","LU1244550494.USD","LU0912757837.SGD","LU1732800096.USD","LU1244550577.SGD","LU2347655073.USD"],"gpt_icon":0},{"id":"2577616183","title":"Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2577616183","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577616183?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  22, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171023/0/en/Vera-Therapeutics-to-Host-an-Investor-Call-and-Webcast-to-Provide-an-ORIGIN-3-Update-on-November-6-2025-at-4-30-pm-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJTD4V19.USD","BK4539","LU1718418525.SGD","LU2133065610.SGD","LU1244550494.USD","LU0417517546.SGD","LU0726765562.USD","BK4550","IE00B7KXQ091.USD","BK4581","TACI","FSGS","LU0942090050.USD","LU2347655073.USD","BK4209","LU1585245621.USD","ET","HST","BK4566","BK4218","LU0868494617.USD","BK4561","LU1074936037.SGD","LU0912757837.SGD","MCD","LU0868494708.USD","IE00BJTD4N35.SGD","IE00BFSS7M15.SGD","LU0795875169.SGD","BK4585","BK4534","LU0256863811.USD","BK4181","BK4588","IE00BJJMRX11.SGD","LU1035773651.USD","LU1069347547.HKD","LU1732799900.SGD","BK4610","LU1244550221.USD","IE0004445015.USD","LU0795875086.SGD","LU2279689827.SGD","VERA","LU1430594728.SGD","LU1732800096.USD","IE00BJJMRY28.SGD","IE00BFSS8Q28.SGD","LU2347655156.SGD","BK4144"],"gpt_icon":0},{"id":"2576272059","title":"Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576272059","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576272059?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:12","pubTimestamp":1760706720,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168657/0/en/Vera-Therapeutics-Announces-ORIGIN-3-Late-Breaking-Abstract-Selected-as-Featured-Oral-Presentation-at-Opening-Plenary-Session-of-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7KXQ091.USD","LU1430594728.SGD","LU1035773651.USD","LU1244550577.SGD","LU0256863811.USD","IE00BJJMRY28.SGD","LU0912757837.SGD","IE00BJTD4N35.SGD","IE00BFSS7M15.SGD","IE00BJTD4V19.USD","LU1244550494.USD","LU1732799900.SGD","BK4610","LU0868494708.USD","BK4585","BK4588","BK4209","FSGS","TACI","VERA","LU1585245621.USD","LU0417517546.SGD","LU1732800096.USD","LU2347655156.SGD","MCD","BK4581","LU1244550221.USD","LU2279689827.SGD","LU2133065610.SGD","IE00BFSS8Q28.SGD","LU0795875086.SGD","LU1069347547.HKD","LU0942090050.USD","BK4566","BK4539","BK4534","LU2347655073.USD","IE00BJJMRX11.SGD","LU0726765562.USD","BK4504","BK4139","BK4550","IE0004445015.USD","LU0868494617.USD","LU1074936037.SGD","LU0795875169.SGD","LU1718418525.SGD"],"gpt_icon":0},{"id":"2569208685","title":"First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2569208685","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569208685?lang=en_us&edition=fundamental","pubTime":"2025-09-22 12:29","pubTimestamp":1758515340,"startTime":"0","endTime":"0","summary":"NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd.  announced that the U.S. Food and Drug Administration  has approved its first-in-human Investigational New Drug  application for LBL-047 on September 19, 2025.LBL-047 is a bispecific fusion protein composed of a humanized anti-blood dendritic cell antigen 2  antibody and an engineered transmembrane activator and CAML interactor  ectodomain independently developed by Leads Biolabs. There are currently no approved clinical trials of drugs targeting both BDCA2 and TACI worldwide. With this unique mechanism of action, LBL-047 holds strong first-in-class potential.By targeting both BDCA2 and BAFF/APRIL, LBL-047 is designed to simultaneously inhibit pDC activity and B-cell maturation, providing a synergistic approach to treating autoimmune diseases such as systemic lupus erythematosus, dermatomyositis, IgA nephropathy and Sjgren's syndrome. LBL-047 is further optimized with glycosylation modifications to enhance a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/first-in-class-potential-fda-clears-ind-application-for-lbl-047-an-anti-bdca2taci-bispecific-fusion-protein-developed-by-leads-biolabs-302562543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","TACI","IND.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TACI\",params:#limit:6,delay:false,,,undefined,":[]}}